ARIX BIOSCIENCE SUPPORTS DEPIXUS, AN EARLY-STAGE COMPANY FOCUSED ON NUCLEIC ACID SEQUENCING & EPIGENETIC ANALYSIS

25th July 2016

LONDON, JULY 25, 2016:

Arix Bioscience Limited (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it has provided equity capital to Depixus, an early-stage company, based in Paris, France that is developing novel technologies for combined genetic and epigenetic analysis.

Arix Bioscience sources, finances and develops businesses addressing medical innovation at all stages of development. Edward Rayner, an employee of Arix Bioscience, has joined the board of Depixus to provide strategic input to the company.

Depixus is developing a core technology platform known as SIMDEQ™ (Single molecule Magnetic Detection and Quantification), on which the goal is to extract genetic and epigenetic information from nucleic acids (DNA & RNA) at levels of detail and accuracy not achievable with current technologies.

“We are delighted to support the exciting innovations underpinning Depixus’s novel approach to genetic and epigenetic analysis. Epigenetics is an important new frontier in understanding the relationship between genes and disease, and has significant potential application in the development of new targeted medicines.”

Dr Joe Anderson, Chief Executive Officer of Arix Bioscience

SIMDEQ™ is based on research coming out of France’s École Normale Supérieure.

Gordon Hamilton, CEO of Depixus, commented: “We are extremely pleased to have the financial and strategic support of Arix, which will help us to accelerate our development programmes and bring forward the timelines for reaching many of our key milestones”.